Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients. (22nd September 2022)

• Record Type: Journal Article
• Authors: Santagata, D.; Cammà, G.; Donadini, M.P.; Squizzato, A.; Ageno, W.
• Is Part Of: Expert opinion on pharmacotherapy. Volume 23:Number 14(2022)
• Page Start: 1651
• Page End: 1665
• Publication Date: 2022-09-22
• Subjects: VTE -- enoxaparin -- fondaparinux -- rivaroxaban -- apixaban -- betrixaban -- thromboprophylaxis -- DOAC -- factor XI inhibitors -- LMWH -- direct oral anticoagulants; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2022.2128757
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Venous thromboembolism (VTE) is a common complication in patients hospitalized for acute medical illnesses. Therefore, medical inpatients require a careful VTE and bleeding risk assessment to drive optimal strategies for VTE prevention. Low molecular weight heparin and fondaparinux have long been used for inhospital prophylaxis for patients at increased risk of VTE. The selection of patients who require post-discharge prophylaxis, and the role of direct oral anticoagulants remain debated. New molecules currently under development may contribute to improve the risk benefit of VTE prevention in this setting. Areas covered: This text summarizes the evidence on approved treatments and on other drugs for the prevention of VTE in acutely ill medical patients. The main focus is on their pharmacological properties, clinical efficacy and safety, and the current license approved by the FDA (Food and Drug Administration) and EMA (European Medicines Agency). The trials presented consider both inhospital and extended prophylaxis. Expert opinion: Thanks to the potentially favorable safety profile, factor XI inhibitors may play a role in the prevention of VTE in this setting. The expert opinion section discusses pharmacological properties, prophylaxis trials, and potential clinical applications of this novel class of drugs.